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Background—Irreversible inhibition of Bruton tyrosine kinase (Btk) by ibrutinib represents a
significant therapeutic advance for chronic lymphocytic leukemia (CLL). However, ibrutinib also
irreversibly inhibits alternative kinase targets, which potentially compromise its therapeutic index.
Acalabrutinib (ACP-196) is a more selective irreversible Btk inhibitor specifically designed to
improve upon the safety and efficacy of first generation Btk inhibitors.
Methods—Sixty-one patients with relapsed CLL were treated in a phase 1–2 multicenter study
designed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of oral
acalabrutinib. Patients were continuously treated with acalabrutinib 100 to 400 mg once daily in
the dose-escalation portion of the study, and 100 mg twice daily in the expansion portion.
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Results—Patient demographics include a median age of 62 years; median of 3 prior therapies;
31% del(17)(p13.1) and 75% unmutated immunoglobulin heavy chain variable genes. No doselimiting toxicities occurred. The most common adverse events observed were headache (43%),
diarrhea (39%) and increased weight (26%). Most adverse events were Grade 1–2. At a median
follow-up of 14.3 months, the best overall response rate was 95%, including 85% partial response,
10% partial response with lymphocytosis and 5% stable disease. In patients with del(17)(p13.1),
the best overall response was 100%. No cases of Richter’s transformation and only 1 CLL
progression have occurred.
Conclusions—Acalabrutinib is a highly selective Btk inhibitor that provides effective and well
tolerated treatment for patients with relapsed CLL, including those with del(17)(p13.1).

Introduction
Author Manuscript
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Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia. While
chemoimmunotherapy prolongs remission duration and overall survival for most CLL
patients,1,2 relapse virtually always occurs. This has prompted aggressive discovery efforts
for new therapies in CLL. As B-cell receptor signaling is a driving factor for CLL tumor cell
survival,3,4 therapeutic targeting of proximal kinases involved in this pathway has occurred.
Bruton tyrosine kinase (Btk) is immediately down-stream of the B-cell receptor and is
essential for activation of several tumor cell survival pathways relevant to CLL.5 In addition,
Btk is involved in chemokine-mediated homing and adhesion of CLL cells to the
microenvironment, which contributes to their maintenance and proliferation.6,7 In mice and
humans, loss of Btk function results in a B-cell directed phenotype with decreased serum
immunoglobulin and increased predisposition to infections. Few other adverse effects have
been reported.8–10 The unique structure of this protein, characterized by a cysteine (C481)
within the ATP-binding pocket, makes this kinase an attractive therapeutic target. Ibrutinib is
a first-in-class, irreversible small molecule inhibitor of Btk with the ability to covalently
bind to C481.11 Ibrutinib showed significant monotherapy activity in relapsed and untreated
patients with CLL.12–14 Progressive disease on ibrutinib is very uncommon in previously
untreated CLL and also in low risk genomic patients.12–14 Among those with high-risk
genomic features, progression is more frequent either shortly after the start of ibrutinib due
to Richter’s transformation (large cell lymphoma) or later with progressive CLL.15 Ibrutinib
also irreversibly binds to other kinases (eg, tyrosine kinase expressed in hepatocellular
carcinoma [Tec], epidermal growth factor receptor [EGFR], interleukin-2-inducible T-cell
kinase [Itk], and T cell X chromosome kinase [Txk]).11 These pharmacologic features may
explain toxicities not typically observed in Btk-deficient patients, such as rash, diarrhea,
arthralgias/myalgias, atrial fibrillation, ecchymosis, and major hemorrhage.12–14
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Acalabrutinib (ACP-196) is a second-generation, highly selective irreversible inhibitor of
Btk with improved pharmacologic features, including rapid oral absorption, a short half-life,
and lack of irreversible targeting to alternative kinases, such as EGFR, Itk and Txk. Given
the success of ibrutinib in relapsed CLL,12–14 we sought to determine if selective targeting
of Btk by acalabrutinib would be clinically effective and differentiated, as measured by
response and side effect profile, which represents the most common reason patients
discontinue ibrutinib treatment.15,16 Furthermore, we hypothesized it might be possible to
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administer acalabrutinib twice daily, thus achieving complete and continuous Btk occupancy
(greater than 95%), without increased toxicities from inhibition of alternative kinases. We
anticipate 24-hour target coverage may reduce drug resistance caused by mutations in the
Btk enzyme and may also lower the rate of Richter’s transformations.

Methods
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Preclinical studies with CLL cells and normal immune cells were performed according to
methods outlined in the Supplementary Appendix after written informed consent as part of
an institutional review board-approved protocol at Ohio State University. The phase 1–2
multicenter study was designed to determine the ideal dose, safety, efficacy,
pharmacokinetics and pharmacodynamics of acalabrutinib in patients with relapsed CLL.
All patients provided written informed consent. An institutional review board approved the
protocol at each site. The study was registered at the clinical trials registry of the National
Institutes of Health (NCT02029443) and was conducted according to the principles of the
Declaration of Helsinki and International Conference on Harmonisation Guidelines for
Good Clinical Practice.
Patients
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Eligibility included a diagnosis of relapsed CLL/small lymphocytic lymphoma as defined by
the International Workshop on Chronic Lymphocytic Leukemia,17 requiring treatment per
the International Workshop on Chronic Lymphocytic Leukemia guidelines; having received
at least 1 prior therapy for CLL; adequate performance status (Eastern Cooperative
Oncology Group performance status ≤ 2) and organ function including creatinine and
bilirubin at least 1.5 times the upper limit of normal and alanine transaminase at least 3
times upper limit of normal; and an absence of active infection. Absolute neutrophil count of
at least 750 per microliter and platelet count of at least 50,000 per microliter was required if
no bone marrow involvement was present, but no restrictions for cytopenia were applied if
CLL bone marrow involvement was present. Exclusion criteria included any malignancy
limiting survival to less than 2 years, need for warfarin therapy (other anticoagulation was
allowed), active gastrointestinal inflammation or malabsorption, and medicines associated
with torsades de points, high grade AV block, or corrected QT interval of 480 ms or greater.
Evaluation and Treatment
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All patients had baseline assessment for interphase cytogenetics, immunoglobulin heavy
chain variable gene mutational analysis, β2-microglobulin and B symptoms. Patients were
successively enrolled to cohorts administering oral acalabrutinib at dosages of 100, 175, 250
and 400 mg once daily as part of the dose-escalation portion of the study or 100 mg twice
daily as part of the phase 2 study. Definition of dose-limiting toxicity included Grade 3 nonhematologic toxicity except for alopecia or nausea, vomiting, or diarrhea that resolved with
an intervention; Grade 4 neutropenia lasting more than 5 days or febrile neutropenia, Grade
4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding; or dosing delay due to
toxicity for more than 7 consecutive days. Escalation to the next cohort was allowed if fewer
than 2 dose-limiting toxicities were noted in 6 patients.
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Patients were evaluated at screening, weekly for the first month, biweekly for the second
month and monthly for 4 months, and every 3 months thereafter with medical history,
physical exam and laboratory studies for signs of toxicity. T cell, natural killer cell, and
monocyte numbers were measured at baseline and before cycles 3, 10, and 16. Serum
immunoglobulins were measured on the same schedule. Adverse events were graded
according to the Common Toxicity Criteria of the National Cancer Institute, Version 4.03.
Hematologic toxicities were graded per International Workshop on Chronic Lymphocytic
Leukemia criteria.17 Study endpoints included overall response rate, progression-free
survival, long-term tolerability, pharmacodynamics and pharmacokinetics. Response
assessments, including radiologic exam, were performed at the end of cycle 2, 4, 6, 9, 12,
15, 18 and 21 for most patients. Bone marrow biopsy was done in all patients at 12 months
or when all other criteria were met for complete response. Response was evaluated based on
the International Workshop on Chronic Lymphocytic Leukemia criteria,17 but did not
consider isolated lymphocytosis as relapse. A partial response in the setting of
lymphocytosis was characterized as a partial response with lymphocytosis.
Pharmacokinetics and Pharmacodynamics
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Detailed pharmacokinetic analyses with a validated assay were performed during cycle 1 of
therapy. Occupancy of Btk by acalabrutinib was measured in peripheral blood mononuclear
cells with the aid of a biotin-tagged analogue probe at baseline, 4 hours post-dose days 1, 8,
and 28, and pre-dose days 2, 8, and 28. Phosphorylation of Btk was measured using an
intracellular flow cytometry assay. Immunoblot analysis was done using methods previously
described.18 The murine thrombosis model has been previously described elsewhere.19
Additional experimental details for laboratory studies are provided in the Supplementary
Appendix.
Study Responsibilities
This study was designed by the first, third and last author together with the sponsor, Acerta
Pharma. The clinical investigators and their research teams collected and evaluated all the
data and assessed all the patients. The sponsor was responsible for analyzing the data.
Investigators had open access to the data and analyses. The first author wrote the first draft
of the manuscript; all authors reviewed the manuscript and approved the final version.
Statistics

Author Manuscript

Results are presented through 01 October 2015. All safety and efficacy analyses included
patients who received acalabrutinib. One patient who discontinued treatment after 8 days
was not evaluable for response. Descriptive statistics were used to summarize the findings.
Wilcoxon Signed-Rank test was performed to assess change from baseline for immune cell
counts, cytokine levels and immunoglobulin levels. Only patients with values at baseline and
for each follow-up visit were included, and multiplicity was not adjusted. Progression-free
survival was defined as time from first dose to documented disease progression or death and
was estimated using Kaplan-Meier methodology.20 Data on progression-free survival were
censored at the last clinical assessment for patients who discontinued treatment without

N Engl J Med. Author manuscript; available in PMC 2016 July 28.

Byrd et al.

Page 5

Author Manuscript

documented disease progression. Non-compartmental pharmacokinetic analyses were done
using validated WinNonlin® software (Certara USA, Princeton NJ).

Results
Pharmacology
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The chemical structures of acalabrutinib and ibrutinib are shown in supplemental Figure S1.
Acalabrutinib shows dose-dependent inhibition of B-cell receptor signaling in primary CLL
cells (supplemental Figure S2a). In kinase inhibition assays, acalabrutinib is a more selective
Btk inhibitor than ibrutinib (supplemental Table S1). These biochemical findings are
physiologically relevant as acalabrutinib does not inhibit EGFR signaling (supplemental
Figure S2b). Also, the lack of Itk inhibition (supplemental Figure S2c) likely explains why
acalabrutinib does not inhibit antibody-mediated killing by natural killer cells of
obinutuzumab-coated CLL cells (supplemental Figure S2d). These findings provide
structural, biochemical and in vitro differentiation of acalabrutinib from ibrutinib. These
data, combined with objective clinical responses in a study of naturally occurring canine Bcell lymphomas, provided justification for clinical development of acalabrutinib in CLL.21
Patient Demographics
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This study includes 61 patients who were sequentially enrolled across 6 global sites and
received at least 1 dose of acalabrutinib. The baseline characteristics are provided in Table 1.
At a median follow-up of 14.3 (range 0.5 to 20) months, 87% (53 of 61 patients) are still
receiving treatment. The primary reasons for discontinuation were 2 investigator/patient
decisions; 1 patient with active autoimmune hemolytic anemia that required additional
therapy; 1 fatal pneumonia; 1 adverse event each of diarrhea, gastritis and dyspnea; and 1
CLL progression.
Pharmacokinetics
ACP-196 was rapidly absorbed and eliminated after oral administration (Figure 1a).
Pharmacokinetic results showed exposure of ACP-196 was dose proportional with no drug
accumulation. Mean half-life was approximately 1 hour across all cohorts. Additional
pharmacokinetic parameters are summarized in supplemental Table S2.
Pharmacodynamics
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Acalabrutinib binding to the C481 residue was assessed in all treatment cohorts with data
summarized in Figure 1b. Notably, starting with the 100-mg once daily dose, Btk occupancy
was complete 4 hours after dosing (99% to 100%) and ranged from 87% to 96% at predose
with once daily dosing. Since acalabrutinib has no plasma accumulation, we explored the
feasibility and safety of 100 mg twice daily dosing. Figure 1c demonstrates improved Btk
occupancy of 99% four hours post-dose and 97% predose on days 8 and 28. The interruption
of B-cell receptor signaling was also assessed by measuring phosphorylated Btk shown in
Figure 1d. After treatment with acalabrutinib, complete loss of phosphorylated Btk was
observed at the respective time points across all cohorts. Assessment of platelet aggregation
derived from blood of patients receiving acalabrutinib or ibrutinib (as positive control)
shows inhibition with the latter, but not the former (supplemental Figure S3). ProN Engl J Med. Author manuscript; available in PMC 2016 July 28.
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inflammatory cytokines decreased significantly from baseline to day 28 of treatment
(supplemental Figure S4).
Safety
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Long-term therapy with acalabrutinib has been well tolerated. The most common adverse
events were headache (43%), diarrhea (39%), increased weight (26%), pyrexia (23%) and
upper respiratory tract infection (23%); most events were Grade 1 or 2 and resolved over
time (Table 2). Severe diarrhea, rash, arthralgia/myalgia, bruising and bleeding events were
rare. No major hemorrhage or atrial fibrillation was noted. Serious adverse events are listed
in supplemental Table S3. Serum IgG, IgA and IgM were measured over time and did not
demonstrate significant change among patients, excluding those receiving intravenous
immunoglobulin (supplemental Figure S5). T cell (CD4+, CD8+), natural killer cell and
monocyte numbers similarly demonstrated no clinically significant change over time
(supplemental Figure S6).
Clinical Response
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The clinical activity of acalabrutinib was rapid and robust, as shown in Figure 2a and 2b,
with 98% of patients (59 of 60) experiencing reduction in lymphadenopathy and 61% (37 of
61) experiencing concomitant treatment-related lymphocytosis (defined as at least a 50%
increase from baseline and above absolute lymphocyte count of 5,000 cells/μL). Despite
substantial reductions in lymphadenopathy, treatment-related lymphocytosis was not as
significant or persistent as reported with ibrutinib12–14 and other B-cell receptor inhibitors22.
Also, in patients with baseline cytopenia, improvements were noted in hemoglobin levels,
platelet count and absolute neutrophil count were noted in the great majority of patients
(supplemental Table S4). In the 16 patients with B symptoms at baseline, resolution
occurred in 88% of patients by cycle 4 and 100% of patients by cycle 9 (supplemental Table
S5).
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With a median follow up of 14.3 months, the best overall response rate including partial
response and partial response with lymphocytosis was 95% (partial response, 85%; partial
response with lymphocytosis, 10%, and stable disease, 5%). Responses were observed
across all cohorts (Figure 2c) and continued to improve over time (Figure 2d). Of the 18
patients with del(17)(p13.1), the response rate was 100% (partial response, 89%; partial
response with lymphocytosis, 11%). In the 4 patients with prior idelalisib therapy, the
response rate was 100% (partial response, 75%, partial response with lymphocytosis, 25%).
At the time of analysis, only 1 patient with del(17p)(p13.1) progressed on therapy with a
newC481S BTK (major clone) and L845F PLCG2 (minor clone) mutation as reported with
ibrutinib treatment23 No cases of Richter’s transformation have been reported. A KaplanMeier plot of progression-free survival is shown in Figure 3. Only 2 events have been noted,
thus far, a death from pneumonia (13 months) and a single progression (16 months).

Discussion
The introduction of irreversible Btk inhibitors such as ibrutinib for treatment of CLL and
other related B-cell lymphoproliferative disorders represents a major therapeutic
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advance.12–14 Concurrent with ibrutinib clinical development, another irreversible Btk
inhibitor, CC-292, was studied in CLL. CC-292 was well tolerated, but demonstrated
inferior clinical results compared with ibrutinib.24,25 At the time, it was suggested CC-292
maybe a more selective inhibitor of Btk than ibrutinib. This introduced the question do
irreversible Btk inhibitors need to inhibit alternative targets, as ibrutinib does, to ensure
efficacy? Herein, we demonstrate acalabrutinib has more selective and different biochemical,
in vitro, in vivo and pharmacokinetic properties as compared with ibrutinib. These
preclinical findings prompted initiation of this first-in-human study in relapsed patients with
CLL, wherein a high response rate and durable remissions have been demonstrated. Notably,
no early Richter’s transformation and only one late CLL progression have occurred even
though this trial included a high-risk relapsed CLL population. Thus, these results support
the conclusion that only Btk inhibition is needed to ensure marked efficacy in CLL.
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Along with this clinical activity, the safety of acalabrutinib was also favorable, despite
prolonged continuous administration. In ibrutinib clinical studies, side effects, such as rash,
diarrhea, blurred vision, atrial fibrillation, arthralgias/myalgias, major hemorrhage
(including subdural hematomas) and bruising/ecchymosis, have been reported.12–14 For
some patients these toxicities have resulted in discontinuation of therapy. Our preclinical
work with acalabrutinib demonstrates many of the alternative kinase targets of ibrutinib,
including EGFR, Itk, Txk, are not influenced at pharmacologic concentrations. Furthermore,
in patients receiving ibrutinib, we demonstrate diminished platelet aggregation, whereas
with acalabrutinib we do not observe this. This finding may reflect why major bleeding
events with acalabrutinib have, thus far, not occurred. In addition, no cases of atrial
fibrillation have been reported to date despite 14 months of follow up at which time many
such events were noted on ibrutinib.13 In contrast, transient headaches appear to be more
common with acalabrutinib than historical experience with ibrutinib, occurring early in
treatment and generally resolving with time. Randomized studies will be required to fully
appreciate differences in adverse events between acalabrutinib and ibrutinib.
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Having an alternative Btk inhibitor with more selective pharmacologic features for clinical
use is attractive and offers the opportunity to improve on efficacy observed with ibrutinib. In
particular, genetic studies using 2 CLL mouse models26,27 and several types of
lymphoma23,28,29 suggest that a selective and potent pharmacologic inhibitor of Btk offers a
potential advance for treating this disease. The short half-life and selective properties of
acalabrutinib allow twice daily dosing with virtually complete and continuous Btk inhibition
without increased toxicities. Twice daily dosing of ibrutinib has not been pursued. For
highly proliferative CLL and other more aggressive B-cell malignancies, twice daily dosing
may improve patient outcomes compared with ibrutinib. Indeed in this study, no cases of de
novo Richter’s transformation have occurred as reported early in treatment with ibrutinib.15
Exploration of acalabrutinib in the treatment of Richter’s transformation is ongoing based
upon this observation.
In summary, data from a highly selective Btk inhibitor, acalabrutinib, provide strong
justification for further clinical investigation examining efficacy and safety compared with
ibrutinib and other CLL therapies. Based on these data and to meet these goals, a
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comparative phase 3 study (NCT02477696) of acalabrutinib versus ibrutinib has
commenced in patients with high-risk, relapsed CLL.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Acalabrutinib Pharmacokinetics and Pharmacodynamics

Panel A shows mean acalabrutinib plasma concentrations over time for the once daily (QD)
and twice daily (BID) cohorts. Panel B shows Btk occupancy for each cohort before (pre)
and 4 hours after (post) dosing on Day 8 (steady-state). For the BID cohort, Btk occupancy
was evaluated for the morning dose only. Box extends from the 25th to 75th percentiles and
whiskers go 1.5 times the interquartile distance per Tukey method. Panel C shows Btk
occupancy over time for the 100-mg BID cohort (n=28). Panel D shows change in
phosphorylated Btk levels over time for all patients.
Btk denotes Bruton tyrosine kinase.
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Figure 2.

Author Manuscript

Response to Acalabrutinib. Panel A shows the median percent change from baseline in
absolute lymphocyte count (ALC) and the sum of products of lymph node diameters (SPD)
in all patients. The bars represent 95% confidence intervals of the median change from
baseline. Panel B shows greatest change from baseline in lymphadenopathy for patients with
baseline lymphadenopathy and at least one on treatment measurement. All measurements
were based on radiologic assessments. Panel C and D provide investigator-assessed best
response by cohort and over time, respectively. In Panel D responses are depicted for all
available patients at each timepoint.
BID denotes twice daily; QD denotes once daily
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Figure 3.

Kaplan-Meier Curve for Progression-free Survival
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Baseline demographics and clinical characteristics
Characteristic

Total (N=61)

Median age (range), years

62 (44–84)

≥65 years, no. (%)

27 (44)

≥70 years, no. (%)

15 (25)

Diagnosis, no. (%)
Chronic lymphocytic leukemia

61 (100)

Performance status, no. (%)
0

22 (36)

1

36 (59)

2

3 (5)

Bulky lymph node disease, no. (%)

Author Manuscript

≥5 cm in diameter

28 (46)

≥10 cm in diameter

3 (5)

Rai risk classification,* no. (%)
Low

1 (2)

Intermediate

19 (31)

High

41 (67)

Median (range) no. of prior therapies

3 (1–13)

Cytopenia at baseline, no. (%)
Absolute neutrophil count ≤1,500 μL

15 (25)

Hemoglobin ≤11.0 g/dL

21 (34)

Platelets ≤100,000/μL

32 (53)

Prognostic factors, no. (%)

Author Manuscript

Unmutated immunoglobulin variable-region heavy-chain gene

38/51 (75)

(17)(p13.1) deletion†

18/59 (31)

(11)(q22.3) deletion†

17/59 (29)

β2-microglobulin >3.5 mg/L

47/58 (81)

*

Rai stage is derived at time of screening for this trial.

†

Determined by local laboratory or medical history.
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Adverse Events
Adverse Event*

All Grades†

Grades 1–2

Grades 3–4

number of patients (percent)

Author Manuscript

Headache

26 (43)

26 (43)

0 (0)

Diarrhea

24 (39)

23 (38)

1 (2)

Increased weight

16 (26)

15 (25)

1 (2)

Pyrexia

14 (23)

12 (20)

2 (3)

Upper respiratory tract infection

14 (23)

14 (23)

0 (0)

Fatigue

13 (21)

11 (18)

2 (3)

Peripheral edema

13 (21)

13 (21)

0 (0)

Hypertension

12 (20)

8 (13)

4 (7)

Nausea

12 (20)

12 (20)

0 (0)

Contusion

11 (18)

11 (18)

0 (0)

Arthralgia

10 (16)

9 (15)

1 (2)

Petechiae

10 (16)

10 (16)

0 (0)

Decreased weight

10 (16)

10 (16)

0 (0)

*

Listed adverse events were reported in at least 15% of patients, on or before the data cutoff date of October 1, 2015, regardless of cause.

†

The all-grade column includes one patient with a Grade 5 event of pneumonia.
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